In summary, we provide the first direct evidence that RET fusion and PD-L1 highly positive advanced NSCLC responds well to the combination of anlotinib and sintilimab, with a progression-free survival exceeding 17 months. This evidence concerns the gene RET and non-small cell lung carcinoma.